GenMark Diagnostics Schedules Fourth Quarter and Year-End 2013 Financial Results Conference Call for March 11, 2014
February 27 2014 - 08:35PM
Business Wire
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it
plans to release its fourth quarter and year-end earnings results
after market close on Tuesday, March 11, 2014. Management will hold
a conference call to review the Company's financial performance
starting at 4:30 p.m. EDT on the same day. The conference call will
be concurrently webcast. The link to the webcast will be available
on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under
the investor relations section and will be archived for future
reference. To listen to the conference call, please dial (877)
312-5847 (US/Canada) or (253) 237-1154 (International) and use the
conference ID number "6963720" approximately five minutes prior to
the start time.
About GenMark
GenMark Diagnostics is a leading provider of automated,
multiplex molecular diagnostic testing systems that detect and
measure DNA and RNA targets to diagnose disease and optimize
patient treatment. Utilizing GenMark's proprietary eSensor®
detection technology, GenMark's eSensor® XT-8 system is designed to
support a broad range of molecular diagnostic tests with a compact,
easy-to-use workstation and self-contained, disposable test
cartridges. GenMark currently markets four tests that are FDA
cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory
Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity
Test. A number of other tests, including HCV Genotyping, 2C19
Genotyping, and 3A4/3A5 Genotyping are available for research use
only. For more information, visit www.genmarkdx.com.
GenMark Diagnostics, Inc.Hany MassaranyPresident/Chief Executive
Officer760-448-4358
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Feb 2024 to Mar 2024
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Mar 2023 to Mar 2024